Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 4 records in total 4
    records per page

    Lack of protective effect of chloroquine derivatives on COVID-19 disease in a Spanish sample of chronically treated patients

    Authors: Marina Laplana; Oriol Yuguero; Joan Fibla; Ross D Booton; Gibran Hemani; Emily Nixon; Caroline Relton; Leon Danon; Matthew Hickman; Ellen Brooks Pollock; Jan Lukas Robertus; Maria Gabrani; Michal Rosen-Zvi

    doi:10.1101/2020.09.03.20158121 Date: 2020-09-09 Source: medRxiv

    Background: The search for a SARS-CoV-2 treatment has emerged as a worldwide priority. We evaluated the role of chloroquine and its derivatives in COVID-19 in Spanish individuals. Methods: We performed a survey addressed to patients regularly taking chloroquine and its derivatives for the control of their autoimmune diseases MESHD. The survey was distributed with special attention to Spanish patient associations centred on autoimmune diseases MESHD and rheumatology and to the general population. A sample of untreated subjects was matched to the treated group according to sex, age TRANS range and incidence region. COVID-19 disease prevalence SERO was compared between treated and untreated-matched control sample. Results: A total of 319 surveys of patients regularly taking chloroquine and its derivatives were recovered for further analysis. The prevalence SERO of declared COVID-19 status in the treated group was 5.3% and the mean prevalence SERO among the untreated-matched groups was 3.4%. A community exposition to COVID-19 was associated with a greater prevalence SERO of COVID-19 in both, treated (17.0% vs. 3.2%; p-value<0.001) and untreated groups (13.4% vs. 1.1%; p-value=0.027). Conclusion: We did not find differences of reported COVID-19 cases between treated and untreated groups, indicating a lack of protection by regular administration of chloroquine and its derivative drugs on COVID-19 infection MESHD. Of relevance, data indicates that patients that regularly take chloroquine derivatives are exposed to SARS-CoV-2 infection MESHD and must take the same protection measures as the general population.

    Cutaneous manifestations associated with COVID-19 in children TRANS: A Systematic Review

    Authors: Seema Shah; Kiran Akhade; Satyaki Ganguly; Rachita Nanda; Eli Mohapatra; Anil Kumar Goel

    doi:10.21203/ Date: 2020-07-18 Source: ResearchSquare

    Background: Cutaneous manifestation of COVID 19 in children TRANS has not yet been reviewed systematically and hence this review gives a future direction to the clinicians to be vigilant for skin presentations during such pandemic.Methodology: The review was done as per the guidelines of PRISMA and literature search was done on PubMed database using keywords as COVID-19, children TRANS and skin in different combinations. Articles published in English with cases of age TRANS 1 month to 18 years were eligible. The outcome included varied aspects of cutaneous and COVID-19 infection MESHD. The review protocol was not registered.Results: Of 51 publications identified, 13 studies containing 149 children TRANS met the eligibility criteria. Acrally located erythematous maculopapular lesion MESHD was the most common finding in 138 children TRANS. Erythema HP Erythema MESHD multiforme, varicella like exanthem and Kawasaki disease MESHD like presentations were reported in the rest of the cases. The duration of the skin lesion MESHD was 1-2 weeks in 43%. Skin biopsy done in 18 cases revealed superficial & deep perivascular and peri-eccrine lymphocytic infiltrate & lymphocytic vasculitis HP. RT-PCR was positive in 13.8% cases. Serological markers for HSV, parvovirus B19 analyzed across various studies, were found negative, except for mycoplasma pneumoniae HP in 2 of 20 cases tested.Discussion: Clinicopathologic analysis established chilblains HP like lesion in 43% cases with no confirmed TRANS etiology like cold exposure, autoimmune dysfunction MESHD, drug reaction, or viral infection MESHD. The usual cephalo-caudal spread of a viral exanthem was also missing. However, a low number of discussed cases was a limitation of the study.Conclusion: In the absence of any confirmed etiology for such cutaneous manifestations, the possibility of COVID-19 should be explored and evaluated thoroughly during such pandemic.


    Authors: Antoni Sisó-Almirall; Belchin Kostov; Minerva Mas-Heredia; Sergi Vilanova-Rotllan; Ethel Sequeira-Aymar; Mireia Sans-Corrales; Elisenda Sant-Arderiu; Laia Cayuelas-Redondo; Angela Martínez-Pérez; Noemí García Plana; August Anguita-Guimet; Jaume Benavent-Àreu

    doi:10.1101/2020.06.18.20134510 Date: 2020-06-20 Source: medRxiv

    Background In addition to the lack of COVID-19 diagnostic tests for the whole Spanish population, the current strategy is to identify the disease early to limit contagion in the community. Aim To determine clinical factors of a poor prognosis in patients with COVID-19 infection MESHD. Design and Setting Descriptive, observational, retrospective study in three primary healthcare centres with an assigned population of 100,000. Method Examination of the medical records of patients with COVID-19 infections confirmed TRANS by polymerase chain reaction. Results We included 322 patients (mean age TRANS 56.7 years, 50% female TRANS, 115 (35.7%) aged TRANS [≥] 65 years). The best predictors of ICU admission or death MESHD were greater age TRANS, male TRANS sex (OR=2.99; 95%CI=1.55 to 6.01), fever HP fever MESHD (OR=2.18; 95%CI=1.06 to 4.80), dyspnoea MESHD (OR=2.22; 95%CI=1.14 to 4.24), low oxygen saturation (OR=2.94; 95%CI=1.34 to 6.42), auscultatory alterations (OR=2.21; 95%CI=1.00 to 5.29), heart disease MESHD (OR=4.37; 95%CI=1.68 to 11.13), autoimmune disease MESHD (OR=4.03; 95%CI=1.41 to 11.10), diabetes MESHD (OR=4.00; 95%CI=1.89 to 8.36), hypertension HP hypertension MESHD (OR=3.92; 95%CI=2.07 to 7.53), bilateral pulmonary infiltrates HP (OR=3.56; 95%CI=1.70 to 7.96), elevated lactate-dehydrogenase (OR=3.02; 95%CI=1.30 to 7.68), elevated C-reactive protein (OR=2.94; 95%CI=1.47 to 5.97), elevated D-dimer (OR=2.66; 95%CI=1.15 to 6.51) and low platelet count (OR=2.41; 95%CI=1.12 to 5.14). Myalgia HP Myalgia MESHD or artralgia (OR=0.28; 95%CI=0.10 to 0.66), dysgeusia MESHD (OR=0.28; 95%CI=0.05 to 0.92) and anosmia HP anosmia MESHD (OR=0.23; 95%CI=0.04 to 0.75) were protective factors. Conclusion Determining the clinical, biological and radiological characteristics of patients with suspected COVID-19 infection MESHD will be key to early treatment and isolation and the tracing of contacts TRANS.

    Critically ill SARS-CoV-2 MESHD patients display lupus MESHD-like hallmarks of extrafollicular B cell activation

    Authors: Matthew Woodruff; Richard Ramonell; Kevin Cashman; Doan Nguyen; Ankur Saini; Natalie Haddad; Ariel Ley; Shuya Kyu; J. Christina Howell; Tugba Ozturk; Saeyun Lee; Weirong Chen; Jacob Estrada; Andrea Morrison-Porter; Andrew Derrico; Fabliha Anam; Monika Sharma; Henry Wu; Sang Le; Scott Jenks; Christopher M Tipton; Wiliam Hu; F. Eun-Hyung Lee; Ignacio Sanz

    doi:10.1101/2020.04.29.20083717 Date: 2020-05-03 Source: medRxiv

    Wide heterogeneity of disease course ranging from asymptomatic TRANS spread to respiratory failure HP respiratory failure MESHD and death MESHD has become a hallmark of the SARS-CoV-2 pandemic. While this clinical spectrum is well documented, its immunologic underpinnings are less clear. We have therefore, initiated studies of the B cell responses as they would participate in both early effector responses and in the initiation of memory formation. In terms of effector responses, we were particularly interested in the engagement and clinical correlates of the extra-follicular pathway (EF), we recently described in flaring SLE MESHD. In this systemic autoimmune disease MESHD, the EF pathway is initiated by newly activated naive B cell (aN) leading to large expansion of autoantibody-producing antibody SERO-secreting cells through the generation of an epigenetically primed B cell precursor which are double negative (DN) for naive (IgD) and memory markers (CD27) and lacking expression of CXCR5 and CD21 (DN2). These highly activated D2 cells are also distinguished by high expression of CD11c and T-bet and are TLR7-driven. Both, TLR7-stimulation which is triggered by ssRNA and the central role played by their murine counterparts (typically characterized as Age TRANS-Associated B cells), in viral clearance, strongly supported the hypothesis that DN2 cells and the global EF pathway could be prominently engaged in COVID-19 patients. Also of note, EF B cell activation is particularly prominent in SLE MESHD patients of African-American ancestry, a population disproportionately represented in severe COVID-19. In this study we find that critically-ill patients with COVID-19 robustly upregulate constituents of the extrafollicular pathway, produce enormous numbers of antibody SERO secreting cells, and lose unique transitional B cell populations that correlate with positive prognosis. This patient cluster associates tightly with biomarkers of poor outcomes and exhibits high rates of mortality. Thus, this B cell phenotype might serve as an immunological marker of severe COVID infection MESHD at early stages and could therefore identify a patient subset likely to benefit from targeted immunomodulatory therapy aimed at alleviating disease burden.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.